Hochdrucktherapie 2015

Ulrich Kintscher; Felix Mahfoud

doi:10.1055/s-0041-102097

DMW - Deutsche Medizinische Wochenschrift, Table of Contents

Dtsch Med Wochenschr 2015; 140(11): 835-844
DOI: 10.1055/s-0041-102097

Fachwissen

CME

Hochdrucktherapie 2015

Therapy of hypertension – 2015

Authors

Ulrich Kintscher

¹Center for Cardiovascular Research (CCR), Institut für Pharmakologie, Charité – Universitätsmedizin Berlin
Felix Mahfoud

²Klinik für Innere Medizin III – Kardiologie, Angiologie und internistische Intensivmedizin, Universitätsklinikum des Saarlandes

Abstract

Zusammenfassung

Die arterielle Hypertonie ist mit einer aktuellen Prävalenz von 32 % weiterhin eine der häufigsten Erkrankungen des Erwachsenenalters in Deutschland. In den neuen ESH / ESC-Leitlinien von 2013 und den praxisnahen Pocketleitlinien der DHL® / DGK von 2014 sind einige Änderungen in Diagnostik und Therapie enthalten, die in der vorliegenden Arbeit besprochen werden. Die Zielblutdruckwerte wurde vereinfacht, so dass bei fast allen Hypertonikern ein Blutdruckwert von < 140 / 90 mmHg angestrebt werden soll. Ausnahmen sind: Diabetiker, ältere Patienten und bei chronischer Niereninsuffizienz mit Proteinurie, bei denen andere Zielblutdruckwerte gelten. Bei der medikamentösen Therapie gab es keine wesentlichen Änderungen. Die renale Denervation muss in randomisiert, kontrollierten Studien in Deutschland weiter kritisch evaluiert werden, um den Stellenwert des Verfahrens abschließend beurteilen zu können. Sie stellt kein alternatives Verfahren zu einer etablierten medikamentösen und nicht medikamentösen Therapie dar.

Abstract

With an prevalence of 32 %, arterial hypertension remains on of the most common diseases among adults in Germany. The ESH / ESC-guidelines from 2013 and the corresponding pocket guidelines of the DHL^®/ DGK from 2014 contain multiple modifications in diagnosis and therapy that are discussed in the present review. Target blood pressure recommendations have been simplified to < 140 / 90 mmHg for almost all hypertensive patients. Exceptions include: diabetic patients, elderly, and patients with chronic kidney disease and proteinuria. The recommentations for pharmacological antihypertensive therapy remained mainly unchanged. Critical evaluation of renal denervation in therapy resistant hypertension requires additional randomized controlled trials in Germany to finally assess the clinical relevance of this intervention. Currently, renal denervation does not provide an alternative strategy for an establihed pharmacological or non-pharmacological approach.

Schlüsselwörter

Hypertonie - Zielblutdruck - Therapieresistenz - Renale Denervation

Keywords

hypertension - target blood pressure - therapy resistance - renal denervation

Full Text

References

Literatur
1 Azizi M, Sapoval M, Gosse P et al. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial. Lancet 2015;
2 Bhatt DL, Kandzari DE, O’Neill WW et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med 2014; 370: 1393-1401
3 Böhm M, Linz D, Ukena C et al. Renal denervation for the treatment of cardiovascular high risk-hypertension or beyond?. Circ Res 2014; 115: 400-409
4 Brinkmann J, Heusser K, Schmidt BM et al. Catheter-based renal nerve ablation and centrally generated sympathetic activity in difficult-to-control hypertensive patients: prospective case series. Hypertension 2012; 60: 1485-1490
5 Daugherty SL, Powers JD, Magid DJ et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation 2012; 125: 1635-1642
6 de la Sierra A, Segura J, Banegas JR et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension 2011; 57: 898-902
7 Diederichs C, Neuhauser H. Regional variations in hypertension prevalence and management in Germany: results from the German Health Interview and Examination Survey (DEGS1). J Hypertens 2014; 32: 1405-1413
8 Esler MD, Böhm M, Sievert H et al. Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36 month results from the SYMPLICITY HTN-2 randomized clinical trial. Eur Heart J 2014; 35: 1752-1759
9 Fadl Elmula FE, Hoffmann P, Fossum E et al. Renal sympathetic denervation in patients with treatment-resistant hypertension after witnessed intake of medication before qualifying ambulatory blood pressure. Hypertension 2013; 62: 526-532
10 Gaddam KK, Nishizaka MK, Pratt-Ubunama MN et al. Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Arch Intern Med 2008; 168: 1159-1164
11 Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension 2010; 55: 399-407
12 Heusser K, Tank J, Engeli S et al. Carotid baroreceptor stimulation, sympathetic activity, baroreflex function, and blood pressure in hypertensive patients. Hypertension 2010; 55: 619-626
13 Jung O, Gechter JL, Wunder C et al. Resistant hypertension? Assessment of adherence by toxicological urine analysis. J Hypertens 2013; 31: 766-774
14 Kandzari DE, Bhatt DL, Brar S et al. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. Eur Heart J 2015; 36: 219-227
15 Kintscher U, Bohm M, Goss F et al. Kommentar zur 2013 ESH / ESC Leitlinie zum Management der arteriellen Hypertonie. Kardiologe 2014; 136: 223-230
16 Krum H, Schlaich MP, Sobotka PA et al. Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study. Lancet 2014; 383: 622-629
17 Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338: b1665
18 Lim SS, Vos T, Flaxman AD et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2224-2260
19 Lobo MD, Sobotka PA, Stanton A et al. Central arteriovenous anastomosis for the treatment of patients with uncontrolled hypertension (the ROX CONTROL HTN study): a randomised controlled trial. Lancet 2015;
20 Mahfoud F, Bohm M. Hypertension: Arteriovenous anastomosis-next panacea for hypertension?. Nat Rev Cardiol 2015; 12: 197-198
21 Mahfoud F, Lüscher TF, Andersson B et al. Expert consensus document from the European Society of Cardiology on catheter-based renal denervation. Eur Heart J 2013; 34: 2149-2157
22 Mahfoud F, Ukena C, Schmieder RE et al. Ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension. Circulation 2013; 128: 132-140
23 Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH / ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31: 1281-1357
24 Neuhauser H, Thamm M, Ellert U. Blood pressure in Germany 2008–2011: results of the German Health Interview and Examination Survey for Adults (DEGS1). Bundesgesundheitsblatt Gesundheitsforschung, Gesundheitsschutz 2013; 56: 795-801
25 Parving HH, Brenner BM, McMurray JJ et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012; 367: 2204-2213
26 Persell SD. Prevalence of resistant hypertension in the United States, 2003–2008. Hypertension 2011; 57: 1076-1080
27 Rodriguez-Manas L, Fried LP. Frailty in the clinical scenario. Lancet 2015; 385: e7-9
28 Rosa J, Widimsky P, Tousek P et al. Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: six-month results from the prague-15 study. Hypertension 2015; 65: 407-413
29 Roush GC, Holford TR, Guddati AK. Chlorthalidone compared with hydrochlorothiazide in reducing cardiovascular events: systematic review and network meta-analyses. Hypertension 2012; 59: 1110-1117
30 Scheffers IJ, Kroon AA, Schmidli J et al. Novel baroreflex activation therapy in resistant hypertension: results of a European multi-center feasibility study. J Am Coll Cardiol 2010; 56: 1254-1258
31 Smithwick RH. Surgical measures in the treatment of hypertensive patients. Bull Med Soc Cty Monroe 1948; 5: 439-445
32 Sobotka PA, Mahfoud F, Schlaich MP et al. Sympatho-renal axis in chronic disease. Clin Research Cardiol 2011; 100: 1049-1057
33 Tsioufis C, Mahfoud F, Mancia G et al. What the interventionalist should know about renal denervation in hypertensive patients: a position paper by the ESH WG on the interventional treatment of hypertension. EuroIntervention 2014; 9: 1027-1035
34 Vonend O, Böhm M, Eckert S et al. Renal denervation in refractory hypertension: Joint Statement of the German Hypertension League DHL eV and the German Societies of Cardiology, Angiology, Nephrology and Radiology. Dtsch Med Wochenschr 2015; 140: 363
35 Worthley SG, Tsioufis CP, Worthley MI et al. Safety and efficacy of a multi-electrode renal sympathetic denervation system in resistant hypertension: the EnligHTN I trial. Eur Heart J 2013; 34: 2132-2140
36 Yusuf S, Teo KK, Pogue J et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-1559
37 Zanchetti A, Mancia G. Longing for clinical excellence: a critical outlook into the NICE recommendations on hypertension management – is nice always good?. J Hypertens 2012; 30: 660-66
38 Mahfoud F, Vonend O, Bruck H et al. Interventionelle renale Sympathikusdenervation zur Behandlung der therapieresistenten Hypertonie. Dtsch med Wochenschr 2011; 136: 2418-2424
39 Mahfoud F, Himmel F, Ukena C et al. Treatment strategies for resistant arterial hypertension. Dtsch Arztebl Int 2011; 108: 725-731